STAT June 28, 2024
Jason Mast

Rocket Pharmaceuticals said Friday that the Food and Drug Administration rejected its gene therapy for an ultra-rare, sometimes fatal immuno-deficiency syndrome, saying the company needed to submit more information to prove it can safely manufacture the product.

The New York-based biotech said the FDA asked for only “limited”...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
FDA approves Eli Lilly Alzheimer’s drug, expanding treatment options in the U.S.
STAT+: FDA approves Eli Lilly’s early Alzheimer’s treatment
Supreme Court to weigh whether the FDA was heavy-handed with flavored e-cigarette products
STAT+: How controversial was the decision by FDA’s Peter Marks to approve Sarepta’s gene therapy? Check its footnotes
FDA Finds Infectious H5N1 Bird Flu Virus In 14% Of Raw Milk Samples

Share This Article